Table 2 Parasitological results and statistical differences between groups four years after doxycycline MDA implementation
| Â | Treatment group | Â | |
|---|---|---|---|
| Â | Doxycycline + ivermectin | Ivermectin only | p-value |
Mf prevalence (%) (95% CI) | 17% (13%-21%) | 27% (19%-35%) | 0.014 |
Mf/mg skin Median (75-95 percentile) | 0 (0-3.5) | 0 (0.37-5.37) | 0.012 |
Nodule prevalence (%) (95% CI) | 19% (15%-23%) | 20% (13%-27%) | 0.776 |
Nodules/person Median (75-95 percentile) | 0 (0-2) | 0 (0-2) | 0.720 |
Mf prevalence in nodule + subjects (%) (95% CI) | 34% (23%-46%) | 54% (33%-74%) | 0.091 |
Mf/mg skin in nodule + subjects Median (75-95 percentile) | 0 (0.71-11.33) | 0 (4.00-64.53) | 0.032 |